Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment

Fineline Cube Apr 27, 2023

Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...

Company Deals

Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization

Fineline Cube Apr 27, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...

Drug Policy / Regulatory

NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings

Fineline Cube Apr 27, 2023

The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...

Company Deals

Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma

Fineline Cube Apr 27, 2023

Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...

Company Deals

LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product

Fineline Cube Apr 26, 2023

Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with...

Company Deals

Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs

Fineline Cube Apr 26, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA

Fineline Cube Apr 26, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...

Policy / Regulatory

Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages

Fineline Cube Apr 26, 2023

The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price...

Company Deals Digital

Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center

Fineline Cube Apr 26, 2023

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor,...

Company Drug

Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial

Fineline Cube Apr 26, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...

Company Deals

Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization

Fineline Cube Apr 26, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...

Company Drug

Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results

Fineline Cube Apr 26, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...

Company Deals

Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech

Fineline Cube Apr 26, 2023

Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...

Company Deals

Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch

Fineline Cube Apr 26, 2023

US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical...

Company

Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China

Fineline Cube Apr 25, 2023

Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...

Company Deals

Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software

Fineline Cube Apr 25, 2023

Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...

Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Posts pagination

1 … 527 528 529 … 661

Recent updates

  • China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight
  • China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access
  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Policy / Regulatory

China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.